z-logo
open-access-imgOpen Access
Pathogenetic treatment of the patient with splenic marginal zone lymphoma complicated by Evans syndrome
Author(s) -
Н. А. Романенко,
Романенко Николай Александрович,
С. С. Бессмельцев,
Бессмельцев Станислав Семёнович,
Kudrat Abdulkadyrov,
Абдулкадыров Кудрат Мугутдинович
Publication year - 2012
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kmj1726
Subject(s) - medicine , evans syndrome , fludarabine , cyclophosphamide , rituximab , neutropenia , splenic marginal zone lymphoma , autoimmune hemolytic anemia , anemia , lymphoma , marginal zone , surgery , gastroenterology , blood transfusion , chemotherapy , splenectomy , spleen , immunology , antibody , b cell
A case report of a patients with splenic marginal zone lymphoma, in whom clinical remission was initially achieved by 5 continuous courses of combined treatment with fludarabine 25 mg/m2 and cyclophosphamide 350 mg/m2 at days 1-3. Nevertheless, 6 months after patient developed a clinical picture of Evans syndrome, characterized by severe hemolytic anemia, thrombocytopenia and neutropenia. Corticosteroid treatment accompanied by blood transfusion was initiated, the effect was marginal and short-lasting. Switch to rituximab monotherapy allowed to archieve complete clinical and hematological remission with full blood count parameters reversal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here